Ashland, MA, United States of America

Sridaran Natesan

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Sanofi. Active years: 2012.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Inventor Profile: Sridaran Natesan**

Introduction

Sridaran Natesan is an innovative inventor based in Ashland, Massachusetts, known for his significant contributions to the field of medical science. His work focuses on developing treatments that address critical health issues, particularly in cancer therapy.

Latest Patents

Sridaran Natesan holds a patent for a composition and method for the treatment of tumors. This invention details a composition that is useful in treating tumors, alongside methods for its creation and application. Notably, the invention includes a method for assaying inhibitors of the activity of Core 1 protein and other proteins of the mitochondrial respiratory complex III.

Career Highlights

Currently, Sridaran is affiliated with Sanofi, a leading global biopharmaceutical company. His role at Sanofi allows him to leverage his expertise in drug development, contributing to advancements in therapeutic strategies for cancer treatment.

Collaborations

Throughout his career, Sridaran has collaborated with esteemed colleagues such as Paul R. August and Waan Jeng Huang. These partnerships enhance his research endeavors and reflect his commitment to developing innovative solutions in healthcare.

Conclusion

Sridaran Natesan exemplifies the spirit of innovation and dedication to improving patient outcomes through his inventive work in tumor treatment. His patent and collaborations underscore his important role in advancing medical science, demonstrating the impactful nature of his contributions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…